Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 101
interventional 74
Observational 21
Registry 6

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 46
Drug|placebo 18
Other 3
Biological 2
Biological|Drug|placebo 2
Biological|Drug 1
Biological|placebo 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
China 21
United States 8
NA 7
Hong Kong 4
France 3
Thailand 3
Bangladesh 1
Belgium 1
Chile|United States|Argentina|Belarus|Brazil|Bulgaria|Canada|Colombia|Costa Rica|Croatia|Dominican Republic|Guatemala|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|North Macedonia|Peru|Philippines|Poland|Puerto Rico|Russian Federation|Serbia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|Vietnam 1
Colombia|France|Germany|Greece|Hungary|Italy|Spain|Taiwan|United Kingdom 1
Czech Republic 1
Czech Republic|Germany 1
Denmark 1
Germany|Greece|United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czech Republic|France|Hungary|Italy|Mexico|Portugal|Spain|United Kingdom 1
India 1
Japan 1
Korea, Republic of 1
Malaysia 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Czechia|Germany|Hong Kong|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|France|Germany|Hungary|Italy|Korea, Republic of|Mexico|Peru|Poland|Russian Federation|Serbia|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|Chile|Colombia|Czechia|Hong Kong|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Peru|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|Turkey 1
United States|Argentina|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Hong Kong|Hungary|Korea, Republic of|Mexico|Netherlands|Philippines|Russian Federation|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Brazil|Colombia|Costa Rica|France|Israel|Italy|Mexico|Panama|Peru|Spain 1
United States|Argentina|China|Germany|Hong Kong|Hungary|Korea, Republic of|Russian Federation|Taiwan|Tunisia|Turkey 1
United States|Australia|Canada|Czechia|France|Germany|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Philippines|Poland|Portugal|Serbia|Spain|Thailand|United Kingdom 1
United States|Australia|Canada|Czechia|Germany|Greece|Hong Kong|Japan|Korea, Republic of|Malaysia|Mexico|Philippines|Poland|Portugal|Spain|Thailand|United Kingdom 1
United States|Australia|Colombia|Mexico 1
United States|Austria|Canada|France|Germany|Italy|Mexico|Spain|Sweden|United Kingdom 1
United States|Bangladesh|Belarus|Bulgaria|China|Ecuador|Georgia|Guatemala|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|Serbia|Singapore|Spain|Sri Lanka|Taiwan|Thailand|Ukraine 1
United States|Belgium|Mexico|Netherlands|Poland|Thailand 1
United States|Canada|France|Russian Federation|United Kingdom 1
United States|France|Hong Kong|Malaysia|Mexico 1
United States|Hong Kong 1
United States|Mexico 1

Sites per Study

Site_count Study_Count
1 41
2 5
4 2
6 1
7 1
8 1
12 2
15 1
17 2
22 1
23 1
26 2
27 1
31 1
35 1
38 1
46 1
74 1
79 1
82 1
86 1
108 1
118 1
127 1
152 1
187 1

Phase

Phase Study_Count
Phase 2 22
Phase 3 16
N/A 13
Phase 4 12
Phase 1 7
Phase 1/Phase 2 3
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 17
2 36
3 11
4 3
NA 7

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 22.0000 7 6.00000 10.00000 NA 20.0000 2.0
1st Qu. 60.0000 14 13.50000 40.75000 NA 76.7500 20.0
Median 94.0000 16 21.00000 69.00000 NA 238.5000 53.5
Mean 119.0769 29 50.33333 83.86364 NaN 239.4375 69.5
3rd Qu. 120.0000 48 72.50000 120.75000 NA 361.0000 95.0
Max. 362.0000 56 124.00000 265.00000 NA 695.0000 200.0

Trial Group Type

group_type Group_Count
Experimental 72
Active Comparator 32
Placebo Comparator 23
NA 7
Other 5
No Intervention 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 56
Single Group Assignment 14
Sequential Assignment 2
NA 2

Primary Purpose

primary_purpose Study_Count
Treatment 70
Basic Science 2
Screening 2

Observational Studies

Studies by Country

Country Study_Count
United States 7
NA 3
China 2
France 2
Germany 1
Germany|United Kingdom 1
India|Lithuania|Sri Lanka 1
Italy 1
Japan 1
Netherlands 1
Spain 1

Sites per Study

Site_count Study_Count
1 14
2 3
4 2
6 1
8 1

Enrollment Metrics

Measure Observational
Min 0
1st Qu 46
Median 100
Mean 50189
3rd Qu 1200
Max 999999

Observation Model

observational_model Study_Count
Cohort 9
Case-Control 6
Case-Only 2
Case Control 2
NA 2

Time Perspective

time_perspective Study_Count
Prospective 14
Retrospective 3
Cross-Sectional 2
NA 2

Registries

Studies by Country

Country Study_Count
Canada 1
China 1
Egypt 1
France 1
Korea, Republic of 1
United States 1

Sites per Study

Site_count Study_Count
1 5
6 1

Enrollment Metrics

Measure Registries
Min 60.000
1st Qu 165.000
Median 450.000
Mean 1013.333
3rd Qu 1650.000
Max 3000.000

Registry Model

observational_model Study_Count
Cohort 5
Case-Crossover 1

Time Perspective

time_perspective Study_Count
Prospective 5
Cross-Sectional 1

Follow-up

target_duration Study_Count
1 Day 1
10 Years 1
12 Months 1
2 Years 1
20 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03222687 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis https://ClinicalTrials.gov/show/NCT03222687 Completed Shandong University 2017-05-31
NCT03214731 Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT03214731 Recruiting Sun Yat-sen University 2020-11-01
NCT03200002 Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis https://ClinicalTrials.gov/show/NCT03200002 Completed Chitwan Medical College 2015-06-30
NCT03174587 Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis https://ClinicalTrials.gov/show/NCT03174587 Completed Corestem, Inc. 2019-03-12
NCT03031925 Detection of Annexin A2 in Systemic Lupus Erythematosus https://ClinicalTrials.gov/show/NCT03031925 Recruiting Centre Hospitalier Universitaire, Amiens 2018-11-09
NCT03021499 Aurinia Renal Response in Active Lupus With Voclosporin https://ClinicalTrials.gov/show/NCT03021499 Completed Aurinia Pharmaceuticals Inc. 2019-09-24
NCT02954939 The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis https://ClinicalTrials.gov/show/NCT02954939 Recruiting The University of Hong Kong 2021-03-31
NCT02949973 Aurinia Early Urinary Protein Reduction Predicts Response https://ClinicalTrials.gov/show/NCT02949973 Completed Aurinia Pharmaceuticals Inc. 2016-12-31
NCT02949349 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis https://ClinicalTrials.gov/show/NCT02949349 Completed Genovate Biotechnology Co., Ltd., 2016-12-30
NCT02936375 The Iguratimod Effect on Lupus Nephritis (IGeLU) https://ClinicalTrials.gov/show/NCT02936375 Recruiting RenJi Hospital 2020-11-30
NCT02770170 Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT02770170 Active, not recruiting Boehringer Ingelheim 2019-12-24
NCT02682407 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 https://ClinicalTrials.gov/show/NCT02682407 Recruiting Omeros Corporation 2020-12-31
NCT02645565 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis https://ClinicalTrials.gov/show/NCT02645565 Completed Jawaharlal Institute of Postgraduate Medical Education & Research 2016-12-31
NCT02630628 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis https://ClinicalTrials.gov/show/NCT02630628 Recruiting The University of Hong Kong 2022-12-31
NCT01639339 Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT01639339 Completed GlaxoSmithKline 2019-07-25
NCT03393013 A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis https://ClinicalTrials.gov/show/NCT03393013 Recruiting Kezar Life Sciences, Inc. 2021-06-30
NCT02547922 Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis https://ClinicalTrials.gov/show/NCT02547922 Active, not recruiting AstraZeneca 2019-11-26
NCT02532790 The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children https://ClinicalTrials.gov/show/NCT02532790 Recruiting Nanjing Children’s Hospital 2020-07-31
NCT02532777 The Research of Standard Diagnosis and Treatment for HSPN in Children https://ClinicalTrials.gov/show/NCT02532777 Recruiting Nanjing Children’s Hospital 2020-07-31
NCT02457221 A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis https://ClinicalTrials.gov/show/NCT02457221 Completed Astellas Pharma Inc 2018-09-10
NCT02260934 Rituximab and Belimumab for Lupus Nephritis https://ClinicalTrials.gov/show/NCT02260934 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-03-12
NCT03385564 An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis https://ClinicalTrials.gov/show/NCT03385564 Recruiting Boehringer Ingelheim 2022-10-31
NCT02226341 ACTHar in the Treatment of Lupus Nephritis https://ClinicalTrials.gov/show/NCT02226341 Recruiting Columbia University 2024-01-31
NCT02141672 AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) https://ClinicalTrials.gov/show/NCT02141672 Completed Aurinia Pharmaceuticals Inc. 2016-07-31
NCT01312727 Hereditary Tubulointerstitial Nephritis https://ClinicalTrials.gov/show/NCT01312727 Completed Assistance Publique - Hôpitaux de Paris 2014-02-28
NCT01273389 An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT01273389 Completed Janssen Research & Development, LLC 2013-09-30
NCT01714817 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis https://ClinicalTrials.gov/show/NCT01714817 Completed Bristol-Myers Squibb 2016-11-21
NCT01580865 Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis https://ClinicalTrials.gov/show/NCT01580865 Completed Ramathibodi Hospital 2017-03-31
NCT01328834 Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis https://ClinicalTrials.gov/show/NCT01328834 Completed Sun Yat-sen University 2011-10-31
NCT04376216 Prednisolone Treatment in Acute Interstitial Nephritis https://ClinicalTrials.gov/show/NCT04376216 Recruiting Region MidtJylland Denmark 2026-09-01
NCT04318600 Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis https://ClinicalTrials.gov/show/NCT04318600 Completed Yan’an Affiliated Hospital of Kunming Medical University 2017-03-01
NCT04146220 Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis https://ClinicalTrials.gov/show/NCT04146220 Completed Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 2019-09-30
NCT04128579 Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis https://ClinicalTrials.gov/show/NCT04128579 Recruiting Equillium 2021-06-30
NCT03943147 An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis https://ClinicalTrials.gov/show/NCT03943147 Recruiting Bristol-Myers Squibb 2023-01-27
NCT03920059 Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT03920059 Recruiting Chulalongkorn University 2025-04-30
NCT03828071 Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis https://ClinicalTrials.gov/show/NCT03828071 Completed Nanjing University School of Medicine 2015-01-01
NCT03664908 Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? https://ClinicalTrials.gov/show/NCT03664908 Completed CHU de Reims 2019-04-04
NCT03610516 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. https://ClinicalTrials.gov/show/NCT03610516 Recruiting Novartis 2021-03-17
NCT03597464 Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin https://ClinicalTrials.gov/show/NCT03597464 Recruiting Aurinia Pharmaceuticals Inc. 2021-08-31
NCT03453619 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies https://ClinicalTrials.gov/show/NCT03453619 Active, not recruiting Apellis Pharmaceuticals, Inc. 2020-04-30
NCT01207297 Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis https://ClinicalTrials.gov/show/NCT01207297 Completed Zhejiang University 2010-03-31
NCT01206569 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis https://ClinicalTrials.gov/show/NCT01206569 Completed Chinese University of Hong Kong 2011-12-31
NCT01203709 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis https://ClinicalTrials.gov/show/NCT01203709 Completed Tuen Mun Hospital 2012-12-31
NCT01085097 Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT01085097 Completed Teva Pharmaceutical Industries 2012-09-30
NCT01056237 Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis https://ClinicalTrials.gov/show/NCT01056237 Completed Nanjing University School of Medicine 2013-06-30
NCT01042457 Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis https://ClinicalTrials.gov/show/NCT01042457 Completed Chulalongkorn University 2011-12-31
NCT00976300 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study https://ClinicalTrials.gov/show/NCT00976300 Completed Institute of Rheumatology, Prague 2008-05-31
NCT00935389 Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria https://ClinicalTrials.gov/show/NCT00935389 Completed Nanjing University School of Medicine 2011-04-30
NCT00881309 To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis https://ClinicalTrials.gov/show/NCT00881309 Completed Nanjing University School of Medicine 2011-04-30
NCT00876616 Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis https://ClinicalTrials.gov/show/NCT00876616 Completed Nanjing University School of Medicine 2011-05-31
NCT02550652 A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) https://ClinicalTrials.gov/show/NCT02550652 Active, not recruiting Hoffmann-La Roche 2019-01-15
NCT02256150 A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis https://ClinicalTrials.gov/show/NCT02256150 Completed Asahi Kasei Pharma Corporation 2019-03-31
NCT00774852 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis https://ClinicalTrials.gov/show/NCT00774852 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2012-12-31
NCT00709722 Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis https://ClinicalTrials.gov/show/NCT00709722 Completed Nippon Kayaku Co., Ltd. 2007-04-30
NCT00705367 Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg https://ClinicalTrials.gov/show/NCT00705367 Completed Bristol-Myers Squibb 2009-01-31
NCT00626197 A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) https://ClinicalTrials.gov/show/NCT00626197 Completed Genentech, Inc. 2009-10-31
NCT00615173 Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis https://ClinicalTrials.gov/show/NCT00615173 Completed Sun Yat-sen University 2008-09-30
NCT00429377 Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study https://ClinicalTrials.gov/show/NCT00429377 Completed Astellas Pharma Inc NA
NCT00423098 Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare https://ClinicalTrials.gov/show/NCT00423098 Completed Novartis 2009-11-30
NCT00404794 A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis https://ClinicalTrials.gov/show/NCT00404794 Completed Hospital Authority, Hong Kong NA
NCT00377637 A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. https://ClinicalTrials.gov/show/NCT00377637 Completed Hoffmann-La Roche 2007-03-31
NCT00371319 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis https://ClinicalTrials.gov/show/NCT00371319 Completed Tuen Mun Hospital 2014-05-31
NCT00302549 To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN https://ClinicalTrials.gov/show/NCT00302549 Completed Nanjing University School of Medicine 2005-05-31
NCT00301613 Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN https://ClinicalTrials.gov/show/NCT00301613 Completed Nanjing University School of Medicine 2005-05-31
NCT00298506 Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) https://ClinicalTrials.gov/show/NCT00298506 Completed Nanjing University School of Medicine 2008-12-31
NCT00282347 A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis https://ClinicalTrials.gov/show/NCT00282347 Completed Genentech, Inc. 2009-01-31
NCT00268567 Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone https://ClinicalTrials.gov/show/NCT00268567 Completed Peking University NA
NCT00204022 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis. https://ClinicalTrials.gov/show/NCT00204022 Completed Université Catholique de Louvain 2011-08-31
NCT00125307 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis https://ClinicalTrials.gov/show/NCT00125307 Completed Chinese University of Hong Kong 2007-10-31
NCT00094380 Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) https://ClinicalTrials.gov/show/NCT00094380 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2006-01-31
NCT00818948 Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis https://ClinicalTrials.gov/show/NCT00818948 Completed Amgen 2014-06-30
NCT00001789 BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis https://ClinicalTrials.gov/show/NCT00001789 Completed National Institutes of Health Clinical Center (CC) NA
NCT00035308 Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease https://ClinicalTrials.gov/show/NCT00035308 Completed La Jolla Pharmaceutical Company NA
NCT00001676 Cyclophosphamide and Fludarabine to Treat Lupus Nephritis https://ClinicalTrials.gov/show/NCT00001676 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03063281 Anti-ficolin-2 Autoantibodies in Lupus Nephritis https://ClinicalTrials.gov/show/NCT03063281 Completed University Hospital, Grenoble 2013-05-31
NCT03001973 High Quality Evidence of Chinese Lupus Nephritis (HELP) https://ClinicalTrials.gov/show/NCT03001973 Recruiting Sun Yat-sen University 2019-12-31
NCT02718027 Biomarker for Alport Syndrome (BioAlport) https://ClinicalTrials.gov/show/NCT02718027 Recruiting Centogene AG Rostock 2023-12-31
NCT02625831 Anti-ficolin-3 Autoantibodies in Lupus Nephritis https://ClinicalTrials.gov/show/NCT02625831 Completed University Hospital, Grenoble 2013-05-31
NCT03180021 Dynamic Imaging of Variation in Lupus Nephritis https://ClinicalTrials.gov/show/NCT03180021 Active, not recruiting RILITE Foundation 2020-09-30
NCT02493101 The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients https://ClinicalTrials.gov/show/NCT02493101 Completed Chulalongkorn University 2015-02-28
NCT02403115 Prediction of Outcome of Lupus Nephritis https://ClinicalTrials.gov/show/NCT02403115 Recruiting Istituto Giannina Gaslini 2019-11-30
NCT01731054 Functional MRI in Lupus Nephritis https://ClinicalTrials.gov/show/NCT01731054 Completed Biogen 2015-03-31
NCT01470183 Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients https://ClinicalTrials.gov/show/NCT01470183 Completed Columbia University 2013-02-28
NCT03836144 Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria https://ClinicalTrials.gov/show/NCT03836144 Recruiting European Georges Pompidou Hospital 2020-12-31
NCT01410747 A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations https://ClinicalTrials.gov/show/NCT01410747 Completed Astellas Pharma Inc 2020-01-31
NCT01338363 Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists https://ClinicalTrials.gov/show/NCT01338363 Completed AstraZeneca 2015-08-31
NCT04347824 Predict Adverse Events by Covid-19 Nephritis https://ClinicalTrials.gov/show/NCT04347824 Recruiting University Hospital Goettingen 2020-12-31
NCT03842787 Anti-ficolin-3 Antibodies in Lupus Nephritis https://ClinicalTrials.gov/show/NCT03842787 Recruiting University Hospital, Grenoble 2020-06-30
NCT03791827 Multicenter Registry of Pediatric Lupus Nephritis in China https://ClinicalTrials.gov/show/NCT03791827 Recruiting Second Xiangya Hospital of Central South University 2023-11-30
NCT03687138 Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques https://ClinicalTrials.gov/show/NCT03687138 Recruiting Hospital de Basurto 2019-06-15
NCT04320797 Urinary T Cell Biomarker for Prediction in Lupus Nephritis https://ClinicalTrials.gov/show/NCT04320797 Recruiting Charite University, Berlin, Germany 2021-09-30
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT00374283 Monitoring of Biopsy-Proven Interstitial Polyomavirus Nephritis in Kidney and Kidney Pancreas Transplant Recipients https://ClinicalTrials.gov/show/NCT00374283 Completed University of Cincinnati NA
NCT00342329 Lupus Nephritis: Role of Environmental and Occupational Exposures https://ClinicalTrials.gov/show/NCT00342329 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001979 Immune System Related Kidney Disease https://ClinicalTrials.gov/show/NCT00001979 Recruiting National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02878018 Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis https://ClinicalTrials.gov/show/NCT02878018 Active, not recruiting Liaoning University of Traditional Chinese Medicine 2019-03-31
NCT01802034 Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) https://ClinicalTrials.gov/show/NCT01802034 Recruiting The Rogosin Institute 2022-08-31
NCT03929887 KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis https://ClinicalTrials.gov/show/NCT03929887 Recruiting Seoul National University Hospital 2028-12-31
NCT03921398 Identifying New Therapeutic Targets for Lupus Treatment https://ClinicalTrials.gov/show/NCT03921398 Recruiting Assistance Publique - Hôpitaux de Paris 2021-05-01
NCT03687905 Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine https://ClinicalTrials.gov/show/NCT03687905 Recruiting Tanta University 2019-03-31
NCT03460054 The Canadian Glomerulonephritis Registry and Translational Research Initiative https://ClinicalTrials.gov/show/NCT03460054 Recruiting University Health Network, Toronto 2022-12-30